Trial of Myocet in Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00294996. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.
Study identification
- NCT ID
- NCT00294996
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 363 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Mar 31, 2009
Started 2006
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Cancer Center Clinical Research | San Diego | California | 92121 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Northwest Hematology/Oncology Associates | Coral Springs | Florida | 33065 | — |
| Osceola Cancer Center | Kissimmee | Florida | 34741 | — |
| UM/Sylvester Cancer Center | Plantation | Florida | 33324 | — |
| John B. Amos Cancer Center | Columbus | Georgia | 31904 | — |
| Clintell, Inc | Skokie | Illinois | 60076 | — |
| Hutchinson Clinic P.A. | Hutchinson | Kansas | 67502 | — |
| Western Maryland Health System | Cumberland | Maryland | 21502 | — |
| Brody School of Medicine @ ECU | Greenville | North Carolina | 27834 | — |
| Aultman Hospital Cancer Center | Canton | Ohio | 44710 | — |
| Hematology Oncology Consultants, Inc. | Columbus | Ohio | 43235 | — |
| Vita Hematology Oncology | Bethlehem | Pennsylvania | 18015 | — |
| Hematology & Oncology Associates of NEPA | Dunmore | Pennsylvania | 18512 | — |
| PA Oncology Hematology Asso | Philadelphia | Pennsylvania | 19106 | — |
| M. Francisco Gonzalez | Columbia | South Carolina | 29203 | — |
| Sioux Valley Clinic | Sioux Falls | South Dakota | 57104 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37920 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00294996, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2009 · Synced Oct 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00294996 live on ClinicalTrials.gov.